Webinars and Sponsored Roundtables — Register Now

Thursday, May 28, 2026, 1:00–2:00 PM ET
This session is designed to improve understanding and application of recent updates to synoptic pathology reporting protocols such as the latest Reporting Template for Reporting Results of Biomarker Testing of Specimens from Patients with Carcinoma of the Breast. These changes reflect evolving clinical guidelines that directly influence diagnostic accuracy and treatment selection in breast cancer care.

Webinar presenters Thaer Khoury, MD, FCAP, Chair, Pathology and Laboratory Medicine, Roswell Park Comprehensive Cancer Cente, and Colin Murphy,  CEO of mTuitive.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Wednesday, June 24, 2026, 12:00–1:00 PM ET
Hear an expert discuss the expanded clinical utility of HER2 IHC scoring in metastatic breast cancer and its impact on your practice

Webinar presenters Michelle Shiller, DO, AP, CP, MGP, FACP, Baylor University Medical Center.

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Subspecialties

Interactive Product Guides

Marketplace

Gene expression assay for Barrett’s esophagus, 11/13

Diagnovus, a molecular diagnostics company focused on underserved, aggressive, and lesser-known diseases, announced the launch of the Engauge GI Barrett’s Esophagus genomic assay to predict the risk of progression to high-grade dysplasia or esophageal adenocarcinoma in Barrett’s esophagus patients.

High-precision pipettors, 11/13

Denville Scientific’s new Ultra EZpette high-precision digital pipettors provide accurate and precise liquid dispensing in an ergonomic design.

Horizon collaborates with Blueprint Medicines, 11/13

Horizon Discovery has signed a research service agreement with Blueprint Medicines, a patient-driven oncology company developing highly selective kinase inhibitors for genomically defined cancer subsets. Under the terms of the deal, Horizon will support Blueprint’s New Targets discovery platform by deploying its X-Man isogenic cell lines.

Navios flow cytometer cleared for diagnostic use, 11/13

Beckman Coulter Life Sciences has received 510(k) clearance from the FDA and an import medical device registration certificate from the China Food and Drug Administration for the in vitro diagnostic use of the Navios flow cytometry system.

Spinal fluid control, 11/13

Audit MicroControls has added Control LQ Spinal Fluid to its line of daily quality control products. This bi-level reference control consisting of human serum-based solutions simulates patient spinal fluid samples for monitoring the precision of laboratory testing procedures for chloride, glucose, IgA, IgG, IgM, lactate, LDH, microalbumin, microprotein, and sodium.

Thrombin generation assay for IVIG product, 11/13

Haemtech Biopharma Services announced the successful validation of a thrombin generation assay for an intravenous immunoglobulin drug. The assay was validated in 2012 to support the use of TGA as a release assay for Biotest Pharmaceuticals’ FDA biologics license application for BIVIGAM, an immune globulin intravenous (human), 10 percent liquid product. The validated TGA assay was designed and performed on the Calibrated Automated Thrombogram platform from Diagnostica Stago.

FDA clears SN-TPE on Terumo system, 11/13

Terumo BCT has received FDA 510(k) clearance for single-needle therapeutic plasma exchange (SN-TPE) on its Spectra Optia apheresis system. This option gives therapeutic apheresis operators the ability to convert to SN-TPE at the beginning or at any time during the procedure, depending on patient needs.

Breast cancer prognostic gene-signature assay, 11/13

NanoString Technologies has received FDA 510(k) clearance for its Prosigna breast cancer prognostic gene signature assay. Based on the PAM50 gene signature, Prosigna is the company’s first FDA-cleared in vitro diagnostic assay and uses the gene-expression profile of cells found in breast cancer tissue to assess a patient’s risk of distant recurrence of disease. The Prosigna assay is performed using the nCounter Dx analy

Spray kills C. difficile spores, 11/13

Bleach-Rite Spray, manufactured by Current Technologies, has been approved by the EPA to kill Clostridium difficile spores on hard, nonporous surfaces in five-minute contact time. Bleach-Rite is a hospital-grade spray disinfectant/cleaner, ready to use at the 1:10 dilution recommended by the CDC, OSHA, and NCCLS. The solution is stabilized for an extended shelf life with an expiration date on every bottle.